# AIBIOS K.K.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aibios-k-k

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: www.aibios.co.jp/
- Total disclosed funding: $7M
- Latest round: Series B (Jun 16, 2021)
- Investors on record: 3

## About

Based in Japan, AIBIOS K.K. is focused on developing innovative preventative healthcare solutions and pharmaceuticals for both humans and animals, utilizing advanced immunotherapy approaches to enhance health outcomes.Founded in 2015, AIBIOS K.K. is engaged in the development of healthcare solutions. The company operates from its headquarters in Tokyo, Japan. In June 2021, AIBIOS successfully raised JPY 770 million during its Series B funding round, attracting investments from SBI Investment and Axil Capital Partners. This funding has been pivotal for the company’s ongoing projects in cancer immunity and their partnership-based drug development initiatives.AIBIOS K.K. specializes in innovative preventative healthcare methods and new pharmaceutical developments for health management, testing, and treatment of humans and animals. Their main offerings include advanced immunotherapy solutions targeting gastrointestinal, oncology, and neuroscience diseases. Collaborating with research institutions, AIBIOS aims to improve health and wellness through personalized treatment solutions, primarily serving veterinary professionals and healthcare providers across Japan, the United States, and Asia.AIBIOS K.K. generates revenue through the development and distribution of its healthcare products, primarily utilizing a B2B model. The company forms partnerships with veterinary clinics, healthcare providers, and research institutions to integrate its advanced therapies into clinical practices. Revenue is derived from direct sales agreements with veterinary practices that purchase AIBIOS's products for treatment, as well as from research partnerships that facilitate the commercialization of new therapies. Specific pricing structures are designed to reflect the premium nature of their offerings.AIBIOS K.K. plans to leverage its recent JPY 770 million Series B funding from June 2021 to further develop its pipeline of healthcare solutions. The company is focusing on advancing its cancer immunity research and is committed to collaborating with medical institutions and pharmaceutical companies to discover new drugs that address unmet medical needs. AIBIOS is also exploring expansion into new markets, particularly targeting increased presence in regions with rising demands for biopharmaceutical solutions.

## Funding rounds

- Series B, Jun 16, 2021, $7M — SBI Investment, Beyond Next Ventures, Axil Capital

## Investors

- SBI Investment (https://capitalatlas.ai/funds/sbi-investment) — Series B
- Beyond Next Ventures (https://capitalatlas.ai/funds/beyond-next-ventures) — Series B
- Axil Capital (https://capitalatlas.ai/funds/axil-capital) — Series B